Photocure ASA reported Hexvix®/Cysview® revenues of NOK 116.8 million in the first quarter of 2024, and EBITDA of NOK 7.9 million following positive operational developments and cost control.
Photocure ASA reported Hexvix®/Cysview® revenues of NOK 116.8 million in the first quarter of 2024, and EBITDA of NOK 7.9 million following positive operational developments and cost control.